In This Article:
-
ADC Therapeutics SA (NYSE: ADCT) has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (OTC: BIOVF) for the development and commercialization of Zynlonta for all hematologic and solid tumor indications outside of the U.S., Greater China, Singapore, and Japan.
-
ADC Therapeutics and Sobi intend to make Zynlonta available following a regulatory decision expected by Q1 of 2023.
-
ADC Therapeutics will receive an upfront payment of $55 million.
-
It is eligible to receive $50 million upon regulatory approval of Zynlonta in third-line diffuse large B-cell lymphoma by the European Commission and up to approximately $330 million in additional regulatory and sales milestones.
-
Related: HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications.
-
ADC Therapeutics will also receive a percentage of sales-based royalties ranging from the mid-teens to the mid-twenties.
-
Sobi will share a portion of select global Zynlonta trial costs.
-
In April 2021, the FDA granted accelerated approval to Zynlonta as the first and only CD19-targeted ADC as a single-agent treatment for adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy.
-
Price Action: ADCT shares closed higher by 2.46% at $9.16 on Thursday.
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.